A Phase 3 interventional study of Adapalene/Benzoyl Peroxide and Adapalene in Acne Vulgaris, sponsored by Galderma R&D. Completed at 62 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing adapalene in Acne Vulgaris — none open to participants now, 2 under way, none of them phase 3. Adapalene · Acne Vulgaris.
Among the 30 studies testing adapalene in Acne Vulgaris, this one has the largest enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 2nd registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 30 studies testing adapalene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
Adapalene: first FDA approval 1996 (DIFFERIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 9 · Phase 4 11
First in 2004; this study’s year is marked. 2 started in 2006.
This study's enrollment of 1,670 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 215 across the 30 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one has the largest enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2006, is one of 20 in phase 3, and was the 1st registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing adapalene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a subject should remain the same during the study.
The primary objective is to demonstrate the superiority in efficacy and assess safety of Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene Topical Gel, 0.1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2.5% (Benzoyl Peroxide Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adapalene/Benzoyl Peroxide Topical Gel
Drug: Adapalene/Benzoyl Peroxide
Adapalene Topical Gel
Drug: Adapalene
Benzoyl Peroxide Topical Gel
Drug: Benzoyl Peroxide
Topical Gel Vehicle
Drug: Topical Gel Vehicle
Drug pages: Adapalene · Benzoyl Peroxide
Topical Gel, One application daily in the evening for 12 weeks
Topical Gel,One application daily in the evening for 12 weeks
Topical Gel, one application daily in the evening for 12 weeks
Topical Gel Vehicle,one application daily in the evening for 12 weeks
Success Rate on the Investigator's Global Assessment
Percentage of subjects rated "Clear" and "Almost Clear" on 5-point scale (0=clear; 4=severe)
Time frame: at week 12
Changes in Inflammatory Lesion Counts
Changes in Inflammatory Lesion Counts equals Week 12 Inflammatory Lesion Counts minus Baseline Inflammatory Lesion Counts
Time frame: from Baseline to week 12
Changes in Noninflammatory Lesion Counts
Change in Noninflammatory Lesion Counts equals Week 12 Noninflammatory Lesion Count minus Baseline Noninflammatory Lesion Count
Time frame: from Baseline to week 12
Percent Change in Inflammatory Lesion Counts
Percent Changes in Inflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100
Time frame: at week 12
Percent Change in Noniflammatory Lesion Counts
Percent Changes in Noninflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100
Time frame: at week 12
Percent Change in Total Lesion Counts
Percent Changes in Total Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100
Time frame: at week 12
Recruitment period: First Subject Enrolled October 2006, Last Subject Enrolled July 2007. Types of locations: Dermatology Clinics, Dermatology Research Centers.
| Milestone | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle |
|---|---|---|---|---|
| Started | 419 | 418 | 415 | 418 |
| Completed | 366 | 369 | 363 | 361 |
| Not completed | 53 | 49 | 52 | 57 |
| Withdrew: Withdrawal by subject | 22 | 23 | 23 | 24 |
| Withdrew: Lost to follow-up | 18 | 19 | 22 | 20 |
| Withdrew: Adverse event | 11 | 1 | 6 | 4 |
| Withdrew: Protocol violation | 2 | 2 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 3 | 0 | 5 |
| Withdrew: Pregnancy | 0 | 1 | 1 | 2 |
| Withdrew: Subject transportation issues | 0 | 0 | 0 | 1 |
Percentage of subjects rated "Clear" and "Almost Clear" on 5-point scale (0=clear; 4=severe)
| Percentage of participants | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle |
|---|---|---|---|---|
| Success Rate on the Investigator's Global Assessment | 37.9 | 21.8 | 26.7 | 17.9 |
Changes in Inflammatory Lesion Counts equals Week 12 Inflammatory Lesion Counts minus Baseline Inflammatory Lesion Counts
| Lesion count | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle |
|---|---|---|---|---|
| Changes in Inflammatory Lesion Counts | -18 (-49 to 50) | -15 (-49 to 50) | -16 (-63 to 38) | -12 (-47 to 95) |
Change in Noninflammatory Lesion Counts equals Week 12 Noninflammatory Lesion Count minus Baseline Noninflammatory Lesion Count
| Lesion count | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle |
|---|---|---|---|---|
| Changes in Noninflammatory Lesion Counts | -28 (-93 to 108) | -24 (-96 to 44) | -23 (-87 to 61) | -18 (-82 to 69) |
Percent Changes in Inflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100
| Percent change | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle |
|---|---|---|---|---|
| Percent Change in Inflammatory Lesion Counts | -61.7 ± 33.9 | -50.1 ± 39.4 | -52.2 ± 39.4 | -40.8 ± 41.1 |
Percent Changes in Noninflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100
| Percent change | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle |
|---|---|---|---|---|
| Percent Change in Noniflammatory Lesion Counts | -55.6 ± 35.3 | -46.0 ± 33.7 | -44.1 ± 37.3 | -32.3 ± 39.5 |
Percent Changes in Total Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100
| Percent change | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle |
|---|---|---|---|---|
| Percent Change in Total Lesion Counts | -57.7 ± 31.9 | -47.5 ± 31.3 | -47.2 ± 32.7 | -35.2 ± 36 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adapalene/Benzoyl Peroxide Gel | — | 3/419 (0.7%) | 90/419 (21.5%) |
| Adapalene Gel | — | 1/418 (0.2%) | 60/418 (14.4%) |
| Benzoyl Peroxide Gel | — | 1/415 (0.2%) | 35/415 (8.4%) |
| Gel Vehicle | — | 2/418 (0.5%) | 22/418 (5.3%) |
| Event | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle |
|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/419 | 0/418 | 1/415 | 0/418 |
| Abscess limbInfections and infestations | 0/419 | 0/418 | 0/415 | 1/418 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 0/419 | 0/418 | 0/415 | 1/418 |
| Schizoaffective disorderPsychiatric disorders | 0/419 | 1/418 | 0/415 | 0/418 |
| FuruncleInfections and infestations | 1/419 | 0/418 | 0/415 | 0/418 |
| AppendicitisInfections and infestations | 1/419 | 0/418 | 0/415 | 0/418 |
| ScoliosisMusculoskeletal and connective tissue disorders | 1/419 | 0/418 | 0/415 | 0/418 |
| Event | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle |
|---|---|---|---|---|
| Dry SkinSkin and subcutaneous tissue disorders | 90/419 | 60/418 | 35/415 | 22/418 |
| Age, Continuous(years) | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle | Total |
|---|---|---|---|---|---|
| Mean | 19.5 ± 6.7 | 18.5 ± 6.3 | 18.9 ± 6.96 | 19.2 ± 7.23 | 19 ± 6.81 |
| Age, Customized(participants) | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle | Total |
|---|---|---|---|---|---|
| 12-17 years | 233 | 241 | 244 | 243 | 961 |
| Between 18 and 64 years | 186 | 177 | 171 | 175 | 709 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle | Total |
|---|---|---|---|---|---|
| Female | 236 | 229 | 230 | 244 | 939 |
| Male | 183 | 189 | 185 | 174 | 731 |
| Region of Enrollment(participants) | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel | Benzoyl Peroxide Gel | Gel Vehicle | Total |
|---|---|---|---|---|---|
| United States | 185 | 185 | 179 | 185 | 734 |
| Canada | 102 | 100 | 100 | 101 | 403 |
| Europe | 132 | 133 | 136 | 132 | 533 |
The record gives a start of Oct 2006, a primary completion of Oct 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adapalene · Benzoyl Peroxide